NSEDCP
BHVN

NJ State Employees Deferred Compensation Plan’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

NJ State Employees Deferred Compensation Plan’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-20,500
Closed -$3.1M – 492
2022
Q3 		$3.1M Hold
20,500
– – 0.53% 44
2022
Q2 		$2.99M Hold
20,500
– – 0.49% 52
2022
Q1 		$2.43M Hold
20,500
– – 0.33% 76
2021
Q4 		$2.83M Hold
20,500
– – 0.36% 72
2021
Q3 		$2.85M Hold
20,500
– – 0.39% 67
2021
Q2 		$1.99M Hold
20,500
– – 0.26% 95
2021
Q1 		$1.4M Buy
20,500
+5,500
+37% +$445K 0.2% 119
2020
Q4 		$1.29M Hold
15,000
– – 0.2% 119
2020
Q3 		$975K Hold
15,000
– – 0.18% 121
2020
Q2 		$1.1M Hold
15,000
– – 0.21% 107
2020
Q1 		$510K Hold
15,000
– – 0.12% 169
2019
Q4 		$817K Hold
15,000
– – 0.14% 151
2019
Q3 		$626K Buy
15,000
+9,000
+150% +$380K 0.11% 180
2019
Q2 		$263K Buy
+6,000
New +$338K 0.05% 465

Other funds holding BHVN

LIP
Liontrust Investment Partners London, United Kingdom $5.86B AUM 23.75% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
MSCM
McElhenny Sheffield Capital Management Dallas, Texas $404M AUM 19.8% 1-Year Est. Return

NJ State Employees Deferred Compensation Plan's BHVN Position: Q4 2022 in Review

NJ State Employees Deferred Compensation Plan sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2022, closing a stake of 20,500 shares — an estimated $3.1M sold.

NJ State Employees Deferred Compensation Plan first reported a position in BHVN in Q2 2019 and held it in 14 quarters. The position peaked at $3.1M in Q3 2022. 7 funds tracked by Wall St. Rank hold BHVN as of Q4 2022.

  • NJ State Employees Deferred Compensation Plan reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2022 after selling out during the quarter.
  • NJ State Employees Deferred Compensation Plan sold 20,500 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2022, an estimated $3.1M.
  • NJ State Employees Deferred Compensation Plan first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q2 2019 and held it in 14 quarters.
  • NJ State Employees Deferred Compensation Plan's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $3.1M in Q3 2022.
  • 7 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2022.

Based on NJ State Employees Deferred Compensation Plan's 13F filing for Q4 2022, filed 26 Jan 2023.